Gianluigi Savarese
Overview
Explore the profile of Gianluigi Savarese including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
312
Citations
5340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Masi S, Dalpiaz H, Savarese G
J Am Coll Cardiol
. 2025 Feb;
85(7):723-726.
PMID: 39918472
No abstract available.
12.
Settergren C, Benson L, Dahlstrom U, Thorvaldsen T, Savarese G, Lund L, et al.
ESC Heart Fail
. 2025 Jan;
PMID: 39871494
Aims: The study aims to examine characteristics and outcomes associated with health-related quality of life (HRQoL) in patients with heart failure (HF) with preserved, mildly reduced and reduced ejection fraction...
13.
Chouairi F, Fudim M, Savarese G, Szabo B, Dahlstrom U, Hage C, et al.
Eur J Heart Fail
. 2025 Jan;
PMID: 39844742
Aims: It is common in heart failure (HF) trials, especially in HF with preserved (HFpEF) and mildly reduced ejection fraction (HFmrEF), to select for increased risk of outcomes ('enrichment'). We...
14.
Laborante R, Paglianiti D, Bianchini E, Galli M, Borovac J, Savarese G, et al.
Eur J Intern Med
. 2025 Jan;
PMID: 39843332
Aims: Data on the early use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients with acute heart failure (HF) are conflicting, and mostly evaluating soft endpoints (i.e., indices of congestion,...
15.
Shahim A, Linde C, Savarese G, Dahlstrom U, Lund L, Hage C
Eur J Heart Fail
. 2025 Jan;
PMID: 39783801
Aims: Guidelines recommend immediate initiation of all four class I guideline-directed medical therapies, renin-angiotensin system inhibitors (RASI) or angiotensin receptor-neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA) and sodium-glucose cotransporter...
16.
Savarese G, Basile C, Adamo M, Anker S, Bayes-Genis A, Bohm M, et al.
Eur J Heart Fail
. 2025 Jan;
PMID: 39777789
Aims: Secondary mitral regurgitation (SMR) and tricuspid regurgitation (TR) are the most common valvular heart diseases in patients with heart failure (HF). Transcatheter edge-to-edge repair (TEER) devices designed for treating...
17.
Inciardi R, Riccardi M, Savarese G, Metra M, Vaduganathan M, Solomon S
Eur J Heart Fail
. 2024 Dec;
27(2):190-193.
PMID: 39675777
No abstract available.
18.
Volterrani M, Seferovic P, Savarese G, Spoletini I, Imbalzano E, Bayes-Genis A, et al.
ESC Heart Fail
. 2024 Dec;
PMID: 39632549
Physicians' adherence to guideline-recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non-cardiologists are less compliant with HF guideline recommendations. This...
19.
Landucci L, Faxen U, Benson L, Dahlstrom U, Carrero J, Savarese G, et al.
Eur J Heart Fail
. 2024 Nov;
27(2):219-227.
PMID: 39592910
Aims: Mineralocorticoid receptor antagonists (MRA) improve outcomes in heart failure with reduced ejection fraction (HFrEF) but are underused. Point prevalent use has been described, but the kinetics of discontinuation and...
20.
Lindberg F, Savarese G
J Am Coll Cardiol
. 2024 Nov;
85(2):117-119.
PMID: 39570239
No abstract available.